Product
PKC412
1 clinical trial
2 indications
Indication
Acute Myeloid LeukemiaIndication
Myelodysplastic SyndromeClinical trial
A Phase I Trial of Escalating Dose of RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDSStatus: Active (not recruiting), Estimated PCD: 2025-12-01